DK3840753T3 - Migalastat til anvendelse i fremgangsmåder til behandling af fabrys sygdom hos patienter, der har en mutation i gla-genet - Google Patents

Migalastat til anvendelse i fremgangsmåder til behandling af fabrys sygdom hos patienter, der har en mutation i gla-genet Download PDF

Info

Publication number: DK3840753T3
Authority: DK; Denmark
Prior art keywords: migalastat; mutation; disease; methods; patients carrying
Prior art date: 2018-08-20

Application number

DK19703514.0T

Other languages

English (en)

Inventor

Elfrida Benjamin

Original Assignee

Amicus Therapeutics Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-08-20

Filing date

2019-01-16

Publication date

2024-10-28

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=65279726&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3840753(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2019-01-16 Application filed by Amicus Therapeutics Inc filed Critical Amicus Therapeutics Inc

2024-10-28 Application granted granted Critical

2024-10-28 Publication of DK3840753T3 publication Critical patent/DK3840753T3/da

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Obesity (AREA)
Hematology (AREA)
Diabetes (AREA)
Heart & Thoracic Surgery (AREA)
Urology & Nephrology (AREA)
Cardiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Enzymes And Modification Thereof (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Zoology (AREA)
Analytical Chemistry (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Wood Science & Technology (AREA)
Biophysics (AREA)
Biotechnology (AREA)
Immunology (AREA)
Microbiology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)

DK19703514.0T 2018-08-20 2019-01-16 Migalastat til anvendelse i fremgangsmåder til behandling af fabrys sygdom hos patienter, der har en mutation i gla-genet DK3840753T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US201862719962P	2018-08-20	2018-08-20
PCT/US2019/013761 WO2020040806A1 (en)	2018-08-20	2019-01-16	Methods of treating fabry disease in patients having a mutation in the gla gene

Publications (1)

Publication Number	Publication Date
DK3840753T3 true DK3840753T3 (da)	2024-10-28

Family

ID=65279726

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK19703514.0T DK3840753T3 (da)	2018-08-20	2019-01-16	Migalastat til anvendelse i fremgangsmåder til behandling af fabrys sygdom hos patienter, der har en mutation i gla-genet

Country Status (25)

Country	Link
US (2)	US20210315875A1 (da)
EP (7)	EP4299117A3 (da)
JP (3)	JP2021535107A (da)
KR (3)	KR20240017128A (da)
CN (1)	CN112888439A (da)
AU (2)	AU2019326252A1 (da)
BR (1)	BR112021003137A2 (da)
CA (1)	CA3110065A1 (da)
CL (3)	CL2021000435A1 (da)
DK (1)	DK3840753T3 (da)
EA (1)	EA202190569A1 (da)
ES (1)	ES2993833T3 (da)
FI (1)	FI3840753T3 (da)
HR (1)	HRP20241454T1 (da)
HU (1)	HUE068783T2 (da)
IL (1)	IL280961A (da)
LT (1)	LT3840753T (da)
MX (2)	MX2021002070A (da)
PL (1)	PL3840753T3 (da)
PT (1)	PT3840753T (da)
RS (1)	RS66094B1 (da)
SG (1)	SG11202101117QA (da)
SI (1)	SI3840753T1 (da)
SM (1)	SMT202400436T1 (da)
WO (1)	WO2020040806A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
HUE027569T2 (en)	2006-05-16	2016-10-28	Amicus Therapeutics Inc	Preparation for the treatment of Fabry disease
CA2715407C (en)	2008-02-12	2022-07-26	Elfrida Benjamin	Method to predict response to pharmacological chaperone treatment of diseases
AU2018277756A1 (en)	2017-05-30	2020-01-23	Amicus Therapeutics, Inc.	Methods of treating fabry patients having renal impairment
EP3749307A1 (en)	2018-02-06	2020-12-16	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
AU2020327019A1 (en)	2019-08-07	2022-03-03	Amicus Therapeutics, Inc.	Methods of treating Fabry disease in patients having a mutation in the GLA gene
US11623916B2 (en)	2020-12-16	2023-04-11	Amicus Therapeutics, Inc.	Highly purified batches of pharmaceutical grade migalastat and methods of producing the same
CN113969313A (zh) *	2021-11-29	2022-01-25	百世诺(北京)医学检验实验室有限公司	罕见遗传病突变基因及其应用
CN116656704B (zh) *	2023-06-01	2024-11-05	华东理工大学	用于治疗法布里病的转基因表达盒
CN116622750B (zh) *	2023-06-01	2024-05-31	上海勉亦生物科技有限公司	优化的人法布里转基因表达盒及其用途

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6274597B1 (en)	1998-06-01	2001-08-14	Mount Sinai School Of Medicine Of New York University	Method of enhancing lysosomal α-Galactosidase A
AU2008232614A1 (en)	2007-03-30	2008-10-09	Amicus Therapeutics, Inc.	Method for the treatment of Fabry disease using pharmacological chaperones
CA2715407C (en)	2008-02-12	2022-07-26	Elfrida Benjamin	Method to predict response to pharmacological chaperone treatment of diseases
CA2829947C (en) *	2011-03-11	2019-01-15	Amicus Therapeutics, Inc.	Dosing regimens for the treatment of fabry disease
WO2014120900A1 (en) *	2013-01-31	2014-08-07	Icahn School Of Medicine At Mount Sinai	Enhanced therapeutic regimens for treating fabry disease
WO2017165164A1 (en) *	2016-03-22	2017-09-28	Amicus Therapeutics, Inc.	Methods of treating fabry disease in patients having the g9331a mutation in the gla gene
TWI875676B (zh) *	2016-07-19	2025-03-11	美商阿米庫斯醫療股份有限公司	治療ert初治的和已經歷ert的患者中之法布瑞氏症
TW201829770A (zh) *	2017-01-10	2018-08-16	美商阿米庫斯醫療股份有限公司	用於治療fabry氏病之重組α-半乳糖苷酶A
AU2018277756A1 (en) *	2017-05-30	2020-01-23	Amicus Therapeutics, Inc.	Methods of treating fabry patients having renal impairment
EP3749307A1 (en) *	2018-02-06	2020-12-16	Amicus Therapeutics, Inc.	Use of migalastat for treating fabry disease in pregnant patients
TW202042812A (zh) *	2019-01-22	2020-12-01	美商阿米庫斯醫療股份有限公司	減少法布瑞氏症患者中之腦血管事件之方法
AU2020327019A1 (en) *	2019-08-07	2022-03-03	Amicus Therapeutics, Inc.	Methods of treating Fabry disease in patients having a mutation in the GLA gene
EP4103178A4 (en) *	2020-02-10	2024-03-20	Amicus Therapeutics, Inc.	Methods of treating fabry disease
KR20220152547A (ko) *	2020-03-06	2022-11-16	아미쿠스 세라퓨틱스, 인코포레이티드	Gla 유전자에 돌연변이를 갖는 환자에서 파브리 질병을 치료하는 방법

2019
- 2019-01-16 MX MX2021002070A patent/MX2021002070A/es unknown
- 2019-01-16 EA EA202190569A patent/EA202190569A1/ru unknown
- 2019-01-16 RS RS20241181A patent/RS66094B1/sr unknown
- 2019-01-16 HR HRP20241454TT patent/HRP20241454T1/hr unknown
- 2019-01-16 EP EP23202185.7A patent/EP4299117A3/en active Pending
- 2019-01-16 US US17/269,890 patent/US20210315875A1/en active Pending
- 2019-01-16 AU AU2019326252A patent/AU2019326252A1/en not_active Abandoned
- 2019-01-16 LT LTEPPCT/US2019/013761T patent/LT3840753T/lt unknown
- 2019-01-16 DK DK19703514.0T patent/DK3840753T3/da active
- 2019-01-16 KR KR1020247003292A patent/KR20240017128A/ko active Pending
- 2019-01-16 EP EP23202183.2A patent/EP4289475A3/en active Pending
- 2019-01-16 SI SI201930852T patent/SI3840753T1/sl unknown
- 2019-01-16 ES ES19703514T patent/ES2993833T3/es active Active
- 2019-01-16 HU HUE19703514A patent/HUE068783T2/hu unknown
- 2019-01-16 KR KR1020217008263A patent/KR20210046729A/ko active Pending
- 2019-01-16 SM SM20240436T patent/SMT202400436T1/it unknown
- 2019-01-16 BR BR112021003137-5A patent/BR112021003137A2/pt unknown
- 2019-01-16 EP EP23202200.4A patent/EP4285990A3/en active Pending
- 2019-01-16 CA CA3110065A patent/CA3110065A1/en active Pending
- 2019-01-16 PL PL19703514.0T patent/PL3840753T3/pl unknown
- 2019-01-16 EP EP23202201.2A patent/EP4285991A3/en not_active Withdrawn
- 2019-01-16 KR KR1020247003291A patent/KR20240017127A/ko active Pending
- 2019-01-16 CN CN201980069272.8A patent/CN112888439A/zh active Pending
- 2019-01-16 EP EP19703514.0A patent/EP3840753B1/en active Active
- 2019-01-16 SG SG11202101117QA patent/SG11202101117QA/en unknown
- 2019-01-16 WO PCT/US2019/013761 patent/WO2020040806A1/en not_active Ceased
- 2019-01-16 EP EP23202199.8A patent/EP4282472A3/en active Pending
- 2019-01-16 FI FIEP19703514.0T patent/FI3840753T3/fi active
- 2019-01-16 PT PT197035140T patent/PT3840753T/pt unknown
- 2019-01-16 EP EP23202198.0A patent/EP4289476A3/en not_active Withdrawn
- 2019-01-16 JP JP2021509744A patent/JP2021535107A/ja active Pending
2021
- 2021-02-18 IL IL280961A patent/IL280961A/en unknown
- 2021-02-19 CL CL2021000435A patent/CL2021000435A1/es unknown
- 2021-02-19 MX MX2024008350A patent/MX2024008350A/es unknown
2023
- 2023-04-25 JP JP2023071652A patent/JP2023106398A/ja active Pending
- 2023-10-02 US US18/479,396 patent/US20240277687A1/en active Pending
2024
- 2024-03-13 CL CL2024000739A patent/CL2024000739A1/es unknown
- 2024-03-13 CL CL2024000741A patent/CL2024000741A1/es unknown
2025
- 2025-07-04 AU AU2025205141A patent/AU2025205141A1/en active Pending
- 2025-07-14 JP JP2025117816A patent/JP2025165955A/ja active Pending

Also Published As

Publication number	Publication date
JP2023106398A (ja)	2023-08-01
CN112888439A (zh)	2021-06-01
EP4299117A3 (en)	2024-02-21
EP4289475A3 (en)	2024-02-21
IL280961A (en)	2021-04-29
ES2993833T3 (en)	2025-01-10
BR112021003137A2 (pt)	2021-05-11
KR20240017128A (ko)	2024-02-06
EP4289476A3 (en)	2024-02-21
MX2021002070A (es)	2021-07-15
EP4282472A3 (en)	2024-02-21
KR20210046729A (ko)	2021-04-28
WO2020040806A1 (en)	2020-02-27
EP3840753A1 (en)	2021-06-30
CA3110065A1 (en)	2020-02-27
PT3840753T (pt)	2024-10-30
KR20240017127A (ko)	2024-02-06
US20210315875A1 (en)	2021-10-14
EP4285991A3 (en)	2024-02-21
RS66094B1 (sr)	2024-11-29
FI3840753T3 (fi)	2024-10-30
AU2025205141A1 (en)	2025-07-31
SMT202400436T1 (it)	2024-11-15
US20240277687A1 (en)	2024-08-22
CL2021000435A1 (es)	2021-10-22
EP4289476A2 (en)	2023-12-13
EP4285990A3 (en)	2024-02-21
SI3840753T1 (sl)	2025-01-31
EP3840753B1 (en)	2024-07-24
LT3840753T (lt)	2024-11-11
CL2024000739A1 (es)	2024-10-04
AU2019326252A1 (en)	2021-02-25
JP2025165955A (ja)	2025-11-05
EP4299117A2 (en)	2024-01-03
EP4282472A2 (en)	2023-11-29
EP4289475A2 (en)	2023-12-13
EP4285990A2 (en)	2023-12-06
JP2021535107A (ja)	2021-12-16
PL3840753T3 (pl)	2025-01-20
CL2024000741A1 (es)	2024-10-04
SG11202101117QA (en)	2021-03-30
MX2024008350A (es)	2024-07-19
HRP20241454T1 (hr)	2024-12-20
HUE068783T2 (hu)	2025-01-28
EP4285991A2 (en)	2023-12-06
EA202190569A1 (ru)	2021-06-01

Publication	Publication Date	Title
DK3840753T3 (da)	2024-10-28	Migalastat til anvendelse i fremgangsmåder til behandling af fabrys sygdom hos patienter, der har en mutation i gla-genet
DK3673080T3 (da)	2023-11-27	Antisense-oligomerer til behandling af lidelser og sygdomme
EP3562514A4 (en)	2020-08-05	GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
DK3858977T5 (da)	2024-08-19	Stamme til forebyggelse og behandling af stofskiftesygdomme, og brugen heraf
DK3906066T5 (da)	2024-08-05	Geneterapikonstruktioner til behandling af wilsons sygdom
MA52709A (fr)	2021-03-31	Administration d'adn
IL290365A (en)	2022-04-01	Methods for treating Fabry disease in patients with a mutation in the gla gene
CY1120454T1 (el)	2019-07-10	Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
DK3526207T3 (da)	2021-11-22	Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter
SG11202011018PA (en)	2020-12-30	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
SG11202011010YA (en)	2020-12-30	1,3-thiazol-2-yl substituted benzamides for the treatment of diseases associated with nerve fiber sensitization
DK3405215T3 (da)	2022-09-19	Fremgangsmåder til behandling af danon-sygdom og andre autofagilidelser
EP3707275A4 (en)	2021-11-10	DOSAGE AND STRATEGY RECOMMENDATIONS FOR THE TREATMENT OF MEDICAL CONDITIONS USING CANNABIS
MA43388A (fr)	2018-10-10	Mutagenèse ciblée d'acides nucléiques du type enzyme à pont berbérine du tabac
DK3303592T3 (da)	2022-05-30	Gen for hanlig sterilitet hos hvede, wms, og den støvknapsspecifikke ekspressionspromotor samt anvendelser deraf
DK3384049T3 (da)	2023-10-02	Fremgangsmåder til associering af genetiske varianter med et klinisk resultat hos patienter, der lider af aldersrelateret makuladegeneration behandlet med anti-VEGF
DK3419672T3 (da)	2023-07-03	Genterapi til behandling af retinal degenerationssygdom
DK3749308T3 (da)	2024-01-22	Behandling af patienter med klassisk fabrys sygdom med migalastat
DK3307277T3 (da)	2020-12-07	Enkeltstrengede oligonukleotider til anvendelse i medicinsk behandling af hudlidelser
DK4114390T3 (da)	2025-02-24	Fremgangsmåder til behandling af fabrys sygdom hos patienter med en mutation i gla-genet
EP3675890A4 (en)	2021-11-03	IMPROVEMENTS IN IGF-1 ANALYSIS, ADJUSTMENT AND DISEASE MANAGEMENT OF NON-NEUROLOGICAL AND / OR NEUROLOGICAL CONDITIONS
EP3372249C0 (en)	2024-03-27	AAV/UPR-PLUS VIRUS, UPR-PLUS FUSION PROTEIN, GENETIC TREATMENT METHOD AND ITS USE IN THE TREATMENT OF NEURODEGENERATIVE DISEASES SUCH AS, AMONG OTHERS, PARKINSON'S DISEASE AND HUNTINGTON'S DISEASE
EP4046609C0 (en)	2025-02-26	EXTENDED PHARMACOLOGICAL RELEASE OPHTHALMIC FORMULATION AND ITS USES
EP3878454A4 (en)	2022-08-24	Use of 3-o-sulfamate-16,16-dimethyl-d-homoequilenin to treat oncological diseases
DK3630114T3 (da)	2024-01-29	Migalastat til behandling af patienter med fabrys sygdom, der har nedsat nyrefunktion